Article Information
History
- August 26, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Rebecca Dowey1,
- Joby Cole1,2,
- A A Roger Thompson1,
- Chenghao Huang3,
- Jacob Whatmore3,
- Ahmed Iqbal2,4,
- Kirsty L Bradley1,
- Joanne McKenzie1,
- Rebecca C Hull1,
- Allan Lawrie1,
- Alison M Condliffe1,
- Endre Kiss-Toth1,
- Ian Sabroe2 and
- Lynne R Prince1,*
- 1Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, United Kingdom
- 2Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom
- 3Faculty of Medicine, Dentistry and Health, University of Sheffield, Sheffield, United Kingdom
- 4Department of Oncology and Metabolism, University of Sheffield, Sheffield, United Kingdom
- ↵*Corresponding author:
Dr Lynne Prince, Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, United Kingdom. L.r.prince{at}sheffield.ac.uk +44 114 2159546
Posted August 26, 2021.
Enhanced neutrophil extracellular trap formation in COVID-19 is inhibited by the PKC inhibitor ruboxistaurin
